The FDA granted approval to Nuvation Bio’s Ibtrozi, an oral drug targeting rare ROS1-positive non-small cell lung cancer mutations, demonstrating high response rates and durable disease control including in brain metastases. This approval introduces a new therapeutic option amidst an evolving landscape of targeted oncology treatments. Concurrently, Bristol Myers Squibb expanded its radiopharmaceutical pipeline through a $350 million licensing deal for Philochem’s diagnostic and therapeutic prostate cancer candidate, OncoACP3, emphasizing ongoing investment in precision oncology. These developments underscore momentum in specialized drug approvals and strategic acquisitions enhancing cancer care portfolios.